Scientific news

Webinaire 1 April 05.30pm (in french)
Registrer here:

https://app.livestorm.co/newcap-1/webinaire-i-etude-clinique-de-phase-1b2a-evaluant-opm-101-doncodesign-precision-medicine-copie?s=07990d74-f7d3-4d34-b457-58b462e81cfc

Discover OPM’s posters!

UEG Week 2024:

• Unveiling the strong safety profile and high target engagement of opm-101, a first-in-class orally available ripk2 inhibitor, in a phase 1 clinical trial in healthy volunteers​​

Authors : L Peyrin-Biroulet, M.D., PhD IHU INFINY – CHRU de NANCY, France; B. Robin Pharm.D, J. Hoflack, PhD, P. Genne, PhD – Oncodesign Precision Medicine, Dijon, France​

AACR 2024:

• “Unlocking the Potential of OPM-383: A Novel LRRK2 Inhibitor in Cancer Therapy”
  Authors: Maria Eugenia Riveiro, Petra Blom, Kenji Shoji, Jan Hoflack
  Oncodesign Precision Medicine S.A., Dijon, France
• “OPM-116, a highly potent and specific PI3Kγ inhibitor to enhance antitumor immunity”
  Authors: Kenji F. Shoji, Oleksandr Levenets, Petra Blom, Maria Eugenia Riveiro, Jan Hoflack
  Oncodesign Precision Medicine S.A., Dijon, France

IBD 2024 :

• “Unveiling the strong safety profile and high target engagement of OPM-101, a first-in-class orally available RIPK2 Inhibitor, in healthy volunteers, a Phase 1 Clinical trial “
  Authors: ROBIN Bruno, Pharm.D. – HOFLACK Jan, PhD. – GENNE Philippe, PhD.
  Oncodesign Precision Medicine S.A., Dijon, France